share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  08/16 17:08

Moomoo AI 已提取核心信息

TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.
TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.
TransCode Therapeutics, Inc.已收到纳斯达克证券市场发出的两封缺陷函。第一封于2024年8月13日收到，通知公司未满足最低买盘价格要求，其普通股未在30个连续业务日中保持每股最低收盘买盘价格1.00美元的要求。第二封信于2024年8月15日收到，表示未达到股东权益要求，报告的股东权益为1,322,274美元，低于所需的2,500,000美元。TransCode Therapeutics计划在纳斯达克听证会之前请求听证，以解决这些不足，并报告了大约370万的业务前股东权益，考虑到2024年7月的股权发行所得净收益。该公司的证券有停牌或退市风险，并不能保证Panel将给予延期或公司会恢复符合纳斯达克的持续上市要求。
TransCode Therapeutics, Inc.已收到纳斯达克证券市场发出的两封缺陷函。第一封于2024年8月13日收到，通知公司未满足最低买盘价格要求，其普通股未在30个连续业务日中保持每股最低收盘买盘价格1.00美元的要求。第二封信于2024年8月15日收到，表示未达到股东权益要求，报告的股东权益为1,322,274美元，低于所需的2,500,000美元。TransCode Therapeutics计划在纳斯达克听证会之前请求听证，以解决这些不足，并报告了大约370万的业务前股东权益，考虑到2024年7月的股权发行所得净收益。该公司的证券有停牌或退市风险，并不能保证Panel将给予延期或公司会恢复符合纳斯达克的持续上市要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间